Log in

Relevant bibliographies by topics / 51-74 (043.3) / Journal articles

To see the other types of publications on this topic, follow the link: 51-74 (043.3).

Journal articles on the topic '51-74 (043.3)'

Author: Grafiati

Published: 30 May 2022

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic '51-74 (043.3).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Shi, Zumin, Minghao Zhou, Baojun Yuan, et al. "Iron intake and body iron stores, anaemia and risk of hyperglycaemia among Chinese adults: the prospective Jiangsu Nutrition Study (JIN)." Public Health Nutrition 13, no. 9 (2009): 1319–27. http://dx.doi.org/10.1017/s1368980009991868.

Full text

Abstract:

AbstractObjectiveFe supplementation has been used to prevent anaemia in China; however, high Fe intake and body Fe stores may increase diabetes risk. The present study aimed to prospectively examine the association between Fe intake/stores and hyperglycaemia, and to assess the joint effects on anaemia.DesignWe followed 1056 healthy adults aged 20 years and older from 2002 to 2007. Body Fe stores were measured. Dietary data were collected using a 3 d food record and FFQ. Hyperglycaemia was defined as fasting plasma glucose >5·6 mmol/l.ResultsOf the participants, 28·8 % were anaemic at baseli

APA, Harvard, Vancouver, ISO, and other styles

2

Ravi, Praful, Lucia Kwak, Wanling Xie, et al. "Docetaxel with androgen deprivation therapy (ADT) and radiotherapy (RT) for high-risk localized prostate cancer (HRLPC): An ICECaP individual patient-data (IPD) meta-analysis of randomized controlled trials (RCTs)." Journal of Clinical Oncology 43, no. 16_suppl (2025): 5013. https://doi.org/10.1200/jco.2025.43.16_suppl.5013.

Full text

Abstract:

5013 Background: There is no established role for the use of docetaxel with ADT and RT for HRLPC, with mixed results seen in prior RCTs. Prior work from ICECaP (Ravi et al, Eur Urol 2024) has shown that patients (pts) with very high-risk disease (i.e. 2 or 3 risk factors [RFs]: Gleason ≥8, PSA >20, ≥cT3 and/or cN1) have the poorest outcomes with RT+ADT for HRLPC, with 5-year metastasis-free survival (MFS) of ≤80%. We aimed to perform an IPD meta-analysis of the role of docetaxel with ADT+RT for HRLPC and specifically evaluate whether patients with very high-risk disease benefit from the add

APA, Harvard, Vancouver, ISO, and other styles

3

Fernandez, Adrian N., Kevin D. Li, Hiren V. Patel, et al. "Injuries With Electric vs Conventional Scooters and Bicycles." JAMA Network Open 7, no. 7 (2024): e2424131. http://dx.doi.org/10.1001/jamanetworkopen.2024.24131.

Full text

Abstract:

ImportanceMicromobility, the use of small vehicles (primarily scooters and bicycles), has become a standard transportation method in the US. Despite broad adoption of electric micromobility vehicles, there is a paucity of data regarding the injury profiles of these vehicles, particularly in the US.ObjectiveTo characterize micromobility injury trends in the US, identify demographic characteristic differences in users of electric and conventional vehicles, and identify factors associated with hospitalization.Design, Setting, and ParticipantsThis cross-sectional study queried the National Electro

APA, Harvard, Vancouver, ISO, and other styles

4

Akinbobola, Olawale, Meredith Ray, Matthew Paul Smeltzer, et al. "Evolution of overall survival (OS) after curative-intent lung cancer surgery in a population-based Mississippi Delta cohort." JCO Oncology Practice 20, no. 10_suppl (2024): 278. http://dx.doi.org/10.1200/op.2024.20.10_suppl.278.

Full text

Abstract:

278 Background: Surgical resection is the most important curative modality for patients with lung cancer, with long-term OS influenced by both surgical quality and cancer biology. We compared surgical care and outcomes over 4 eras in the population-based Mid-South Quality of Surgical Resection (MS-QSR) cohort, an ongoing regional surgical and pathologic quality improvement (QI) dissemination and implementation project. Methods: We implemented a surgical lymph node collection kit and a novel pathology gross dissection method across 12 hospitals encompassing >95% of lung cancer resections in

APA, Harvard, Vancouver, ISO, and other styles

5

Battista, Marie-Claude, Mélissa Labonté, Julie Ménard, et al. "Dietitian-coached management in combination with annual endocrinologist follow up improves global metabolic and cardiovascular health in diabetic participants after 24 months." Applied Physiology, Nutrition, and Metabolism 37, no. 4 (2012): 610–20. http://dx.doi.org/10.1139/h2012-025.

Full text

Abstract:

This 24 month study evaluated the effect of dietitian coaching combined with minimal endocrinologist follow up on the glycemic control and cardiovascular risks of diabetic participants, compared with conventional endocrinologist follow up. Participants with type 1 or type 2 diabetes were assigned to either the control group with conventional endocrinologist follow up (C; n = 50) or the dietitian-coached group (DC; n = 51) with on-site diabetes self-management education every 3 months combined with annual endocrinologist followup. Over the 24 month intervention, weight (–0.7 vs. +2.1 kg; p = 0.

APA, Harvard, Vancouver, ISO, and other styles

6

Cangiarella, Joan, Kinga Eliasz, Adina Kalet, Elisabeth Cohen, Steven Abramson, and Colleen Gillespie. "A Preliminary Evaluation of Students' Learning and Performance Outcomes in an Accelerated 3-Year MD Pathway Program." Journal of Graduate Medical Education 14, no. 1 (2022): 99–107. http://dx.doi.org/10.4300/jgme-d-21-00284.1.

Full text

Abstract:

ABSTRACT Background Little outcome data exist on 3-year MD (3YMD) programs to guide residency program directors (PDs) in deciding whether to select these graduates for their programs. Objective To compare performance outcomes of 3YMD and 4-year MD (4YMD) students at New York University Grossman School of Medicine. Methods In 2020, using the Kirkpatrick 4-level evaluation model, outcomes from 3 graduating cohorts of 3YMD students (2016–2018) were compared with the 4YMD counterparts. Results Descriptive statistics compared outcomes among consented student cohorts: 92% (49 of 53) 3YMD, 87% (399 o

APA, Harvard, Vancouver, ISO, and other styles

7

Atkins, Michael B., John M. Kirkwood, Jedd D. Wolchok, et al. "Long-term follow-up of CA209-004: A phase I dose-escalation study of combined nivolumab (NIVO) and ipilimumab (IPI) in patients with advanced melanoma." Journal of Clinical Oncology 37, no. 15_suppl (2019): 9533. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.9533.

Full text

Abstract:

9533 Background: We previously reported a 3-year overall survival (OS) rate of 63% with NIVO+IPI concurrent therapy in the initial phase I dose-escalation study for the combination, conducted in patients (pts) with advanced melanoma. Here, we report OS after 5 years of overall study follow-up and assess survival rates after stopping treatment. Methods: Adults with previously treated or untreated unresectable stage III or IV melanoma, and ECOG performance status of 0 or 1, received NIVO + IPI Q3W × 4 as mg/kg in one of the following cohorts: (1) NIVO 0.3 + IPI 3; (2) NIVO 1 + IPI 3; (2a) NIVO 3

APA, Harvard, Vancouver, ISO, and other styles

8

Abdullaiev, R. Ya, A. S. Yefimenko, L. A. Sysun, et al. "İŞEMİK İNSULT OLAN XƏSTƏLƏRDƏ YUXU ARTERİYASI ATEROSKLEROZUNUN SONOQRAFİK XÜSUSİYYƏTLƏRİ." Azerbaijan Medical Journal, no. 1 (March 28, 2024): 5–12. http://dx.doi.org/10.34921/amj.2024.1.001.

Full text

Abstract:

The article presents the results of sonographic diagnosis of carotid atherosclerosis in 127 patients with ischemic stroke (IS) aged 38-74 year (average age 56±7 years). The comparison group (CG) consisted of 51 people with risk factors for cardiovascular diseases without a history of stroke. It has been established that arterial hypertension and type 2 diabetes mellitus are significantly more common among patients with IS than in patients of CG. The frequency of localization of atherosclerotic plaques on the walls of the carotid arteries was determined depending on the course of the stroke. Se

APA, Harvard, Vancouver, ISO, and other styles

9

Charaya, K. V., D. Yu Schekochikhin, T. V. Nikiforova, et al. "The use of Dapagliflozin in Acute Decompensated Heart Failure: Results of the Randomized Study." Kardiologiia 63, no. 8 (2023): 11–18. http://dx.doi.org/10.18087/cardio.2023.8.n2221.

Full text

Abstract:

Aim To determine the effect of sodium-glucose cotransporter-2 inhibitors (SGLT2i) on kidney function in acute decompensated heart failure (ADHF).Material and methods A controlled randomized study on the dapagliflozin treatment in ADHF was performed. Patients were randomized to a main group (standard therapy supplemented with dapagliflozin) or a control group (standard therapy for ADHF). The primary endpoint was the development of acute kidney injury (AKI). 200 patients were included (mean age, 74±12 years; 51% men). 31% of patients had type 2 diabetes mellitus (DM2). Mean left ventricular ejec

APA, Harvard, Vancouver, ISO, and other styles

10

Villa, Diego, Laurie H. Sehn, Kerry J. Savage, et al. "Bendamustine and rituximab as induction therapy in both transplant-eligible and -ineligible patients with mantle cell lymphoma." Blood Advances 4, no. 15 (2020): 3486–94. http://dx.doi.org/10.1182/bloodadvances.2020002068.

Full text

Abstract:

Abstract Rituximab-containing chemotherapy regimens constitute standard first-line therapy for mantle cell lymphoma (MCL). Since June 2013, 190 patients ≥18 years of age with MCL in British Columbia have been treated with bendamustine and rituximab (BR). The overall response rate to BR was 88% (54% complete response). Of these, 61 of 89 patients (69%) aged ≤65 years received autologous stem cell transplantation and 141 of 190 patients (74%) from the entire cohort received maintenance rituximab. Twenty-three patients (12%) had progressive disease, associated with high risk per the Mantle Cell L

APA, Harvard, Vancouver, ISO, and other styles

11

McCullough, Peter A., Marlies Ostermann, Lui G. Forni, et al. "Serial Urinary Tissue Inhibitor of Metalloproteinase-2 and Insulin-Like Growth Factor-Binding Protein 7 and the Prognosis for Acute Kidney Injury over the Course of Critical Illness." Cardiorenal Medicine 9, no. 6 (2019): 358–69. http://dx.doi.org/10.1159/000502837.

Full text

Abstract:

Introduction: Over the course of critical illness, there is a risk of acute kidney injury (AKI), and when it occurs, it is associated with increased length of stay, morbidity, and mortality. The urinary cell-cycle arrest markers tissue inhibitor of metalloproteinase-2 (TIMP-2) and insulin-like growth factor binding protein 7 (IGFBP7) have been utilized to predict the risk of AKI over the next 12 h from the time of sampling. The aim of this analysis was to evaluate the utility of [TIMP-2] × [IGFBP7] measured serially to anticipate the occurrence of AKI over the first 7 days of critical illness.

APA, Harvard, Vancouver, ISO, and other styles

12

Saldaña, Kathryn, Kaddy Revolorio, Gwendolyn Carlson, et al. "0443 Life Values Expressed by Female Veterans Engaged in an Acceptance and Commitment-based Behavioral Therapy for Primary Insomnia." Sleep 45, Supplement_1 (2022): A197. http://dx.doi.org/10.1093/sleep/zsac079.440.

Full text

Abstract:

Abstract Introduction Women Veterans disproportionately suffer from insomnia, which negatively impacts health and overall quality of life. Insomnia can result in fewer value-based choices and less engagement in meaningful life activities. This study sought to identify common life values expressed by women Veterans engaged in an acceptance-and commitment-based behavioral therapy for primary insomnia. Methods 74 female-identifying Veterans (mean age=48.3 years; 47.3% non-Hispanic White, 28.4% Black/African American, 23.0% Hispanic/Latina, 12.2% American Indian/Alaska Native, 5.4% Asian American

APA, Harvard, Vancouver, ISO, and other styles

13

Darehed, David, Mathias Blom, Eva-Lotta Glader, Johan Niklasson, Bo Norrving, and Marie Eriksson. "In-Hospital Delays in Stroke Thrombolysis." Stroke 51, no. 8 (2020): 2536–39. http://dx.doi.org/10.1161/strokeaha.120.029468.

Full text

Abstract:

Background and Purpose: Intravenous thrombolysis is a well-established treatment for acute ischemic stroke. Our aim was to quantify the effect of each minute delay in door-to-needle time (DNT) on 90-day survival, intracerebral hemorrhagic complication <36 hours, and functional outcomes at 3 months, in routine clinical practice. Methods: Our nationwide registry-based study included 14 132 adult patient admissions with ischemic stroke receiving intravenous thrombolysis from 2010 to 2017. Outcomes were analyzed using multivariable logistic regression, adjusting for potential confounders. Resul

APA, Harvard, Vancouver, ISO, and other styles

14

Gunn, G. Brandon, Adam S. Garden, Rong Ye, et al. "Proton Therapy for Head and Neck Cancer: A 12-Year, Single-Institution Experience." International Journal of Particle Therapy 8, no. 1 (2021): 108–18. http://dx.doi.org/10.14338/ijpt-20-00065.1.

Full text

Abstract:

Abstract Purpose To characterize our experience and the disease control and toxicity of proton therapy (PT) for patients with head and neck cancer (HNC). Patients and Methods Clinical outcomes for patients with HNC treated with PT at our institution were prospectively collected in 2 institutional review board–approved prospective studies. Descriptive statistics were used to summarize patient characteristics and outcomes. Overall survival, local-regional control, and disease-free survival were estimated by the Kaplan-Meier method. Treatment-related toxicities were recorded according to the Comm

APA, Harvard, Vancouver, ISO, and other styles

15

Zinzani, Pier Luigi, Thomas E. Witzig, Julie M. Vose, et al. "Confirmation of the Efficacy and Safety of Lenalidomide Oral Monotherapy in Patients with Relapsed or Refractory Mantle-Cell Lymphoma: Results of An International Study (NHL-003)." Blood 112, no. 11 (2008): 262. http://dx.doi.org/10.1182/blood.v112.11.262.262.

Full text

Abstract:

Abstract Introduction: Mantle-cell lymphoma (MCL) is a type of B-cell non-Hodgkin lymphoma (NHL) that typically responds to initial chemo-immunotherapy, but with a relatively short duration of response (DR) and progression-free survival (PFS) when treated with conventional chemotherapy agents. Although the overall survival (OS) of MCL has improved, most patients are not cured and new agents are needed. A sub-analysis of a recent phase II trial (NHL-002) investigating the efficacy and safety of lenalidomide in patients with relapsed or refractory MCL, demonstrated a promising overall response r

APA, Harvard, Vancouver, ISO, and other styles

16

Ravandi, Farhad, Jorge E. Cortes, Daniel Jones, et al. "Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia." Journal of Clinical Oncology 28, no. 11 (2010): 1856–62. http://dx.doi.org/10.1200/jco.2009.25.4888.

Full text

Abstract:

Purpose To determine the efficacy and toxicity of the combination of sorafenib, cytarabine, and idarubicin in patients with acute myeloid leukemia (AML) younger than age 65 years. Patients and Methods In the phase I part of the study, 10 patients with relapsed AML were treated with escalating doses of sorafenib with chemotherapy to establish the feasibility of the combination. We then treated 51 patients (median age, 53 years; range, 18 to 65 years) who had previously untreated AML with cytarabine at 1.5 g/m2 by continuous intravenous (IV) infusion daily for 4 days (3 days if > 60 years of

APA, Harvard, Vancouver, ISO, and other styles

17

Oran, Betul, Richard E. Champlin, Jorge E. Cortes, et al. "Allogeneic Hematopoietic Stem Cell Transplantation (HCT) in First Remission Improves Outcome Irrespective of FLT3-ITD Allelic Burden Among Patients with Acute Myeloid Leukemia and FLT3-ITD Mutation." Blood 124, no. 21 (2014): 2531. http://dx.doi.org/10.1182/blood.v124.21.2531.2531.

Full text

Abstract:

Abstract Presence of internal tandem duplication in the FMS-like tyrosine kinase 3 gene(s) (FLT3-ITD) is associated with poor outcome among patients with cytogenetically normal acute myelogenous leukemia (CN-AML). Patients carrying a higher FLT3-ITD allelic burden have worse outcome. Allogeneic stem cell transplantation (SCT) in first remission (CR1) is reported to improve survival in this poor risk patients. We investigated the impact of FLT3-ITD allelic burden, number of FLT3-ITD mutations and SCT with a matched related or unrelated donor in CR1 in newly diagnosed FLT3-ITD mutated intermedia

APA, Harvard, Vancouver, ISO, and other styles

18

Lam, Julia, Peter Svensson, and Per Alstergren. "Internet-Based Multimodal Pain Program With Telephone Support for Adults With Chronic Temporomandibular Disorder Pain: Randomized Controlled Pilot Trial." Journal of Medical Internet Research 22, no. 10 (2020): e22326. http://dx.doi.org/10.2196/22326.

Full text

Abstract:

Background Chronic pain from temporomandibular disorders remains an undertreated condition with debate regarding the most effective treatment modalities. Objective The aim of the study was to investigate the treatment effect of an internet-based multimodal pain program on chronic temporomandibular disorder pain and evaluate the feasibility of a larger randomized controlled trial. Methods An unblinded randomized controlled pilot trial was conducted with 43 participants (34 females, 9 males; median age 27, IQR 23-37 years) with chronic temporomandibular pain. Participants were recruited within t

APA, Harvard, Vancouver, ISO, and other styles

19

Habib, Diane, Hagop M. Kantarjian, Fadi G. Haddad, et al. "Updated Results of the Combination of Mini-Hyper-CVD with Inotuzumab Ozogamicin and Blinatumomab in Patients with Relapsed/Refractory B-Cell ALL." Blood 144, Supplement 1 (2024): 2811. https://doi.org/10.1182/blood-2024-210501.

Full text

Abstract:

Background: The sequential combination of mini-Hyper-CVD (mini-HCVD) with inotuzumab ozogamicin (INO) and blinatumomab (Blina) improved the outcome of patients (pts) with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) with a tolerable safety profile. Here, we report updated results from a phase II trial including the “dose-dense” (D-D) administration of INO and Blina in combination with chemotherapy with longer follow-up. Methods: Pts ≥18 years with R/R B-ALL were eligible for this phase II trial. All pts received mini-HCVD (cyclophosphamide and dexamethasone at 50% dose

APA, Harvard, Vancouver, ISO, and other styles

20

Aljawai, Yosra M., Rima M. Saliba, George Chen, et al. "Improved Outcomes of Haploidentical Hematopoietic Stem Cell Transplantation with Younger Donors." Blood 144, Supplement 1 (2024): 7442. https://doi.org/10.1182/blood-2024-210407.

Full text

Abstract:

Background: An increasing number of older patients are undergoing hematopoietic stem cell transplantation (HCT). Optimal donor selection is critical for driving positive outcomes post-HCT. Older patients are more likely to have older siblings as potential donors and recent reports have associated older donor age with worse outcomes. In the absence of a suitable matched donor, haploidentical (haplo) donors may be used. However, haplo HCT has been associated with worse non-relapse mortality (NRM) in older patients. Here, we determined if donor age was associated with outcomes in older patients (

APA, Harvard, Vancouver, ISO, and other styles

21

Estevez, Laura G., Isabel Calvo, Maria Fernandez Abad, et al. "A retrospective study in the Spanish population with Oncotype dx recurrence score (RS) in breast cancer patients with positive and negative-lymph nodes." Journal of Clinical Oncology 31, no. 15_suppl (2013): e11531-e11531. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e11531.

Full text

Abstract:

e11531 Background: The international guidelines include the use of Oncotype DX as a predictor of chemotherapy (CT) benefit in hormonal sensitive breast cancer patients (pts) with node negative and node positive (1-3 positive nodes) disease.The aim of this study was to assess the distribution of the RS in breast cancer pts regardless lymph nodes status, and the association with treatment recommendations. Methods: Retrospectivedata from 131 pts with invasive breast cancer for which the OncotypeDX Assay had been ordered, and pathology data were available. Estrogen (ER) and progesterone (PR) recep

APA, Harvard, Vancouver, ISO, and other styles

22

Borel, Christian, Hélène Carinato, Carole Pflumio, et al. "Weekly paclitaxel (P), carboplatin (CP) plus pembrolizumab (PMB) as first-line treatment of recurrent or metastatic (R/M) or locally very advanced (LVA) head and neck squamous cell carcinoma (HNSCC): A retrospective study in 39 patients (pts)." Journal of Clinical Oncology 42, no. 16_suppl (2024): e18018-e18018. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.e18018.

Full text

Abstract:

e18018 Background: Since the results of the KN-048 trial, the combination of platinum/5FU plus PMB has become the standard of care (SOC) for R/M HNSCC pts. The KN-B10 study shows that 5FU can be replaced by P with a favorable response rate and toxicity profile. Weekly use of P reduces hematologic toxicity and increases dose-intensity. Methods: We retrospectively reviewed all records of patients with R/M or LVA (T4b and/or N3b) HNSCC, ECOG-PS 0 to 2, PDL1 CPS ≥ 1, treated in first-line with weekly P (80 mg/m2) and CP (AUC 2: maximum total dose of 250 mg and systematic G-CSF at D3 and D4) for up

APA, Harvard, Vancouver, ISO, and other styles

23

Mieze, K., A. Kivite-Urtane, D. Grinberga, B. Velika, I. Pudule, and E. Rancans. "Sequences for reporting on mild and serious types of suicidal behaviours: A population-based study in Latvia in 2010-2018." European Psychiatry 65, S1 (2022): S838. http://dx.doi.org/10.1192/j.eurpsy.2022.2170.

Full text

Abstract:

Introduction Latvia is listed as a country with one of the highest suicide mortality rates in European Union (National Statistical System of Latvia, 2021). Objectives To assess the sequences for reporting of suicidal behaviours (SB) in Latvian general population. Methods The study is based on secondary data of the Health Behaviour Among Latvian Adult Population survey, provided by the Centre for Disease Prevention and Control of Latvia (representative sample of the Latvian population aged 15-64 in 2010, 2012, 2014; 15-74 in 2016, 2018; (n=16,105). Respondents were asked to report the occurrenc

APA, Harvard, Vancouver, ISO, and other styles

24

Karki, M. "Effect of Supplementation of soybean Cake and Fishmeal with Lysine and Methionine in Broiler Diets on the Growth Performance of Turkey Poults." Nepal Agriculture Research Journal 7 (May 22, 2009): 70–74. http://dx.doi.org/10.3126/narj.v7i0.1871.

Full text

Abstract:

The study was carried out during June to August 2003, using one hundred and eight day oldturkey poults which were randomly divided into twelve groups, 9 birds in each. Three replicatewere allocated to each four dietary treatments. Commercially available broiler feed (Ratna feed)was considered as basal diet (Diet-1), Diet-2 was prepared by addition of lysine (0.3%) +methionine (0.1%) to Diet-1, Diet-3 was prepared by supplementation of soybean cake (15%) +lysine (0.2%) + methionine (0.1%) to Diet-1and Diet-4 was formulated by addition of soybeancake (10%) + fishmeal (5%) in Diet-1. Each diet wa

APA, Harvard, Vancouver, ISO, and other styles

25

Suero-Abreu, Giselle Alexandra, Miguel Gonzalez Velez, Marshall McKenna, et al. "Comprehensive analysis of tumor mutational load, genomic alterations, and PD-L1 status in gastrointestinal cancers using a multiplatform molecular profiling tool." Journal of Clinical Oncology 36, no. 5_suppl (2018): 93. http://dx.doi.org/10.1200/jco.2018.36.5_suppl.93.

Full text

Abstract:

93 Background: Tumor mutational load (TML) has been proposed as a biomarker of responsiveness to novel immune checkpoint inhibitors (ICIs) due its association with increased neoantigen formation and tumor immunogenicity. Gastrointestinal cancers (GICs) are generally insensitive to ICIs; therefore the aim of this study was to evaluate the TML, clinically relevant genomic alterations (CRGAs), and PDL-1 status of GIC patients (pts). Methods: We analyzed samples of pts with GICs using a multiplatform profiling tool (Caris Life Sciences, Phoenix, AZ). TML and CRGAs were calculated based on next gen

APA, Harvard, Vancouver, ISO, and other styles

26

Chiappella, Annalisa, Claudio Agostinelli, Maurizio Martelli, et al. "The Prognostic Role of Cell of Origin Profile and Myc Expression Assessed By Immunohistochemistry in Young High-Risk Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Results of First-Line Randomized BIO-DLCL04 Trial of Fondazione Italiana Linfomi (FIL)." Blood 126, no. 23 (2015): 5041. http://dx.doi.org/10.1182/blood.v126.23.5041.5041.

Full text

Abstract:

Abstract Background. The prognostic role of cell of origin profile (COO) assessed by immunohistochemistry (IHC) is controversial in Rituximab era. FIL conducted a phase III randomized trial aimed at investigating the benefit of intensification with high dose therapy plus autotransplant compared to R-dose-dense therapy as first line in young DLBCL at poor risk (aa-IPI 2-3). Clinical results were reported (Vitolo, ASH 2012). The aim of BIO-DLCL04 was to correlate the biological markers with PFS. Patients and Methods. From 2005 to 2010, 412 untreated DLBCL at aa-IPI 2-3 were enrolled. Central his

APA, Harvard, Vancouver, ISO, and other styles

27

Seryapina, Yu V., D. V. Fedyaev, and N. Z. Musina. "Analysis of demographic, social and economic impacts of proximal femur fracture's surgical treatment for geriatric patients in Russia." Russian Journal of Geriatric Medicine, no. 2 (August 1, 2021): 201–10. http://dx.doi.org/10.37586/2686-8636-2-2021-191-200.

Full text

Abstract:

Objective. Evaluation of influence on mortality, life expectancy and related costs in the Russian Federation of methodical changes in the organizing surgical treatment of proximal femur fracture (PFF).Material and methods. The mathematical modeling methods were applied for evaluation of impacts, related to methodical changes in the organizing surgical treatment of PFF, including the calculation of life expectancy. It is assumed, that 95% of all patients over 60 years old with PFF would receive a surgical treatment. Calculations were perform in 3 stages: calculation of death causes, related to

APA, Harvard, Vancouver, ISO, and other styles

28

Vitolo, Umberto, Annalisa Chiappella, Ercole Brusamolino, et al. "Rituximab Dose-Dense Chemotherapy Followed by Intensified High-Dose Chemotherapy and Autologous Stem Cell Transplantation (HDC+ASCT) Significantly Reduces the Risk of Progression Compared to Standard Rituximab Dose-Dense Chemotherapy As First Line Treatment in Young Patients with High-Risk (aa-IPI 2–3) Diffuse Large B-Cell Lymphoma (DLBCL): Final Results of Phase III Randomized Trial DLCL04 of the Fondazione Italiana Linfomi (FIL)." Blood 120, no. 21 (2012): 688. http://dx.doi.org/10.1182/blood.v120.21.688.688.

Full text

Abstract:

Abstract Abstract 688 Introduction. The prognosis of young DLBCL patients at high risk treated with standard R-CHOP is still rather poor. The role of intensified HDC+ASCT in first line treatment is still a matter of debate in the Rituximab era. The FIL planned a prospective randomized phase III trial with a 2×2 factorial design aimed at investigating the possible benefit of intensification with R-HDC+ASCT after R-dose-dense chemotherapy delivered at two different level of dose (R-CHOP14/R-MegaCHOP14). Patients and methods. The primary end-point was to increase 2-year Progression Free Survival

APA, Harvard, Vancouver, ISO, and other styles

29

Smith, Lane M., R. Wayne Barbee, Kevin R. Ward, and Roland N. Pittman. "Prolonged tissue Po2 reduction after contraction in spinotrapezius muscle of spontaneously hypertensive rats." American Journal of Physiology-Heart and Circulatory Physiology 287, no. 1 (2004): H401—H407. http://dx.doi.org/10.1152/ajpheart.00980.2002.

Full text

Abstract:

We tested the hypothesis that a deficit in oxygen extraction or an increase in oxygen demand after skeletal muscle contraction leads to delayed recovery of tissue oxygen tension (Po2) in the skeletal muscle of hypertensive rats compared with normotensive rats. Blood flow and Po2 recovery at various sites in the spinotrapezius muscle of spontaneously hypertensive rats (SHRs) were evaluated after a 3-min period of muscle contraction and were compared with corresponding values in Wistar-Kyoto rats (WKYs). The recovery of tissue Po2 [75 ± 7 (SHRs) vs. 99 ± 12% (WKYs) of resting values] and venular

APA, Harvard, Vancouver, ISO, and other styles

30

Sorror, Mohamed L., Barry Storer, Brenda M. Sandmaier, et al. "Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning for Patients (pts) Aged ≥60 Years." Blood 112, no. 11 (2008): 2162. http://dx.doi.org/10.1182/blood.v112.11.2162.2162.

Full text

Abstract:

Abstract Median ages of pts with most hematological malignancies are beyond 60 years. The advent of nonmyeloablative conditioning regimens has extended the use of allogeneic HCT to these older pts. Here, we retrospectively investigated outcomes among 280 pts aged ≥60 years, given HCT between 1998 and 2006. Results were broken down in 3 age groups 60–64 (n=166), 65–69 (n=90), and ≥70 (n=24) years old, respectively. Pts aged ≥70 years had less preceding chemotherapy, less often failed autologous HCT, more often had related grafts, and had higher comorbidity scores compared to pts in the other tw

APA, Harvard, Vancouver, ISO, and other styles

31

Kollu, Vidya, Kohei Osterloth, Andrew J. Borgert, Susan M. Frankki, and Benjamin Marshall Parsons. "Impact of endocrine therapy on overall survival in ER negative/PR positive locoregional breast cancer: An analysis of the National Cancer Database." Journal of Clinical Oncology 39, no. 15_suppl (2021): 545. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.545.

Full text

Abstract:

545 Background: Breast cancer expressing PR, but not ER (ER-/PR+) are uncommon, comprising 2–8% of breast cancers, with less known about their characteristics and responsiveness to therapy. The role of adjuvant endocrine therapy (ET) in ER-/PR+ locoregional breast cancer is unclear as these patients have been largely excluded from prospective clinical trials. Despite a lack of data patients are often treated with adjuvant ET due to perceived possible benefit. We used the National Cancer Data Base (NCDB) to assess role of adjuvant ET in ER-/PR + breast cancer. Methods: Using the NCDB, we includ

APA, Harvard, Vancouver, ISO, and other styles

32

Goyal, Gautam, Arun Chandrasekharan, Manuprasad Avaronnan, et al. "Real-world experience of checkpoint inhibitors across India: CRSF 2020-01." Journal of Clinical Oncology 41, no. 16_suppl (2023): e18862-e18862. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e18862.

Full text

Abstract:

e18862 Background: There are limited data available from India on the real-world use of checkpoint inhibitors. Hence we did this analysis across India to study the pattern of use and outcomes with checkpoint inhibitors. Methods: This was a retrospective multicentric protocol. Patients who received immunotherapy from January 2016 to October 2021 were included. The baseline demographic, previous treatment, response, date of progression, date of death and status were noted. SPSS version 20 was used for analysis. Descriptive statistics were performed. Kaplan Meier method was used for estimation of

APA, Harvard, Vancouver, ISO, and other styles

33

Hecquet, S., M. B. Rabier, M. Lepelley, et al. "POS0697 OPHTHALMOLOGICAL ADVERSE EVENTS UNDER JAK: CASE ANALYSIS OF THE EUROPEAN PHARMACOVIGILANCE DATABASE." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 628.1–628. http://dx.doi.org/10.1136/annrheumdis-2022-eular.3356.

Full text

Abstract:

BackgroundOphthalmological manifestations in rheumatic diseases include dry syndrome, scleritis, episcleritis, uveitis and peripheral ulcerative keratitis (PUK). Among the target therapies, JAK inhibitors (JAKinhib) are the most recent to have been approved in rheumatic diseases, rheumatoid arthritis (RA) and spondyloarthritis (SpA), but also in other indications such as inflammatory bowel disease.ObjectivesThe aim of this work is to describe and characterise ophthalmological events in patients exposed to JAKinhib based on European pharmacovigilance (PV) data.MethodsThe ophthalmological manife

APA, Harvard, Vancouver, ISO, and other styles

34

Lambadiari, Vaia, George Pavlidis, Foteini Kousathana, et al. "Effects of Different Antidiabetic Medications on Endothelial Glycocalyx, Myocardial Function, and Vascular Function in Type 2 Diabetic Patients: One Year Follow–Up Study." Journal of Clinical Medicine 8, no. 7 (2019): 983. http://dx.doi.org/10.3390/jcm8070983.

Full text

Abstract:

Background: Poor glycaemic control affects myocardial function. We investigated changes in endothelial function and left ventricular (LV) myocardial deformation in poorly controlled type 2 diabetics before and after glycaemic control intensification. Methods: In 100 poorly-controlled diabetic patients (age: 51 ± 12 years), we measured at baseline and at 12 months after intensified glycaemic control: (a) Pulse wave velocity (PWV, Complior); (b) flow-mediated dilatation (FMD, %) of the brachial artery; (c) perfused boundary region (PBR) of the sublingual arterial micro-vessels (side-view dark-fi

APA, Harvard, Vancouver, ISO, and other styles

35

Arranz, Isabel, Carsten Mischke, Joerg Stroka, et al. "Liquid Chromatographic Method for the Quantification of Zearalenone in Baby Food and Animal Feed: Interlaboratory Study." Journal of AOAC INTERNATIONAL 90, no. 6 (2007): 1598–609. http://dx.doi.org/10.1093/jaoac/90.6.1598.

Full text

Abstract:

Abstract An interlaboratory trial for determination of zearalenone (ZON) in baby food and animal feed was conducted. The study involved 39 participants in 16 European Union member states, as well as Turkey, Uruguay, and China, representing a cross-section of industry, and official food control and research institutes. The method is based on immunoaffinity column cleanup followed by high-performance liquid chromatography using fluorimetry (HPLC-Fl). The test portion of the sample is extracted with methanolwater (75 + 25, v/v). The sample extract is filtered, diluted, and passed over an immunoaf

APA, Harvard, Vancouver, ISO, and other styles

36

Mehta, Rohtesh S., Rima M. Saliba, Kai Cao, et al. "Ex Vivo Mesenchymal Precursor Cell-Expanded Cord Blood Transplantation Following Reduced Intensity Conditioning Regimens." Blood 126, no. 23 (2015): 1190. http://dx.doi.org/10.1182/blood.v126.23.1190.1190.

Full text

Abstract:

Abstract Introduction: Double-unit cord blood (CB) transplantation (DCBT) after myeloablative conditioning, where one CB unit is expanded ex-vivo with mesenchymal precursor cells (MPC)-co-culture led to significantly improved neutrophil and platelet engraftment compared to historical controls.1 Our aim was to determine the efficacy of this technique after reduced-intensity conditioning (RIC) regimens. Methods: We evaluated consecutive adult patients with hematological malignancies who received RIC regimens followed by DCBT where one unit was infused unmanipulated and second unit was expanded e

APA, Harvard, Vancouver, ISO, and other styles

37

Escamilla, Virginia, Jose Falantes, Cristina Calderon, et al. "Prognostic Impact of Adverse Karyotype and Treatment in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia." Blood 126, no. 23 (2015): 5241. http://dx.doi.org/10.1182/blood.v126.23.5241.5241.

Full text

Abstract:

Abstract INTRODUCTION Karyotype is a key prognostic factor in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Adverse karyotype (AK) significantly influences on response to treatment, prognosis and survival in older MDS and AML patients(pts)1,2. AIMS Evaluate the frequency of adverse karyotype over the total number of patients (pts) diagnosed with MDS and AML in our institution, demographic features, treatment received and overall survival (OS) estimates. Second, to analyze prognostic factors associated to OS in this cohort of pts. PATIENTS AND METHODS A retrospective and obs

APA, Harvard, Vancouver, ISO, and other styles

38

Offer, J. E., and N. W. Offer. "Calcium hydroxide treatment of malt distillers' grains 1. Effects on chemical composition and digestibility measuredin vitroandin sacco." Animal Science 55, no. 2 (1992): 203–8. http://dx.doi.org/10.1017/s0003356100037466.

Full text

Abstract:

AbstractExperiment 1 investigated the effects of calcium hydroxide (Ca(OH)2)treatment (80 g/kg malt distillers' grains (MDG) dry matter (DM) at ambient temperature (L) and at 60°C (LH). Organic matter digestibilitiesin vitro(1V0MD) were 0·30, 0·50 and 0·56 (s.e. 0·023) for untreated (C), L and LH respectively. The increase in IVOMD was less with MDG that had previously been ether-extracted (corresponding values 0·47, 0·53 and 0·54). The proportion of lipid in soap form was 0·03, 0·35 and 0·46 (s.e. 0·03) for C, L and LH respectively. Experiment 2 investigated the effects of treatment time, tem

APA, Harvard, Vancouver, ISO, and other styles

39

Liao, Wei, Matthew Paul Smeltzer, Jordan Goss, et al. "Lung cancer diagnosis rates (LCDR) in lung cancer screening (LCS) and incidental pulmonary nodule (IPN) cohorts in the Mississippi Delta." Journal of Clinical Oncology 43, no. 16_suppl (2025): 8002. https://doi.org/10.1200/jco.2025.43.16_suppl.8002.

Full text

Abstract:

8002 Background: The LCDR in the CT screened cohort in the National Lung Screening Trial (NLST) was 1.1% over a median of 6.5 years follow up. We evaluated the LCDR in a regional US community. Methods: Prospective cohort study of patients in LCS and IPN programs in 22 facilities across a 125 county service area population. We compared LCDR over 3 years in LCS stratified by Lung-RADS (L-R) score (1 to 4X), IPN by nodule size (≤6, >6-15, >15-20, >20-30 mm) on initial CT scans. Comparisons used Chi-square tests, Wilcoxon tests, and Cox regression models with Hazard Ratios (HR) for lung c

APA, Harvard, Vancouver, ISO, and other styles

40

Hu, Xichun, Jian Zhang, Rujiao Liu, et al. "Phase I study of A166 in patients with HER2-expressing locally advanced or metastatic solid tumors." Journal of Clinical Oncology 39, no. 15_suppl (2021): 1024. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.1024.

Full text

Abstract:

1024 Background: A166 is an antibody-drug conjugate composed of a novel cytotoxic drug (Duo-5, anti-microtubule agent) site-specifically conjugated to an anti-HER2 antibody (transtuzumab) via a stable protease-cleavable valine citrulline linker. In a phase I trial in US patients (pts) with relapsed or refractory advanced solid tumor, A166 had an acceptable toxicity profile and best objective response rate (ORR) of 36% at efficacious dose levels (Yongheng Liu et al. ASCO 2020). Here we report a phase I study of A166 in Chinese pts with locally advanced or metastatic solid tumors (CTR20181301).

APA, Harvard, Vancouver, ISO, and other styles

41

Joshi, Monika, Matthew Kaag, Leonard Tuanquin, et al. "Phase II clinical study of concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: Results for primary analyses and survival. BTCRC-GU15-023." Journal of Clinical Oncology 39, no. 6_suppl (2021): 398. http://dx.doi.org/10.1200/jco.2021.39.6_suppl.398.

Full text

Abstract:

398 Background: Bladder cancer (BC) patients (pts) who are cisplatin ineligible/unfit for surgery, or locally advanced and unresectable have limited treatment options. DUART investigates if the combination of radiation therapy (RT) and checkpoint inhibitor, durvalumab (durva) is safe and effective in these pts. We recently reported that the combination was safe, tolerable and disease control rate (DCR) was 92% post durvaRT. Here we present interim efficacy data of our phase II study. Methods: Pts with pure or mixed urothelial bladder cancer (T2-4 N0-2 M0) were enrolled if their tumor was unres

APA, Harvard, Vancouver, ISO, and other styles

42

van Lierde, Marie-Anne, Eric Strobbe, Larissa De Rop, et al. "Promoting Patient (pt) Adherence (PA) with Imatinib Treatment (IMRx) in Chronic Myeloid Leukemia (CML): Physicians (MD) Perceptions of Utility (Effectiveness [FX], Feasibility [FB], Cost [CO]) and Rankings of Clinical Applicability (CAPL) of 13 Adherence-Enhancing Strategies (AESs) - Results from the ADAGIO Study." Blood 110, no. 11 (2007): 5165. http://dx.doi.org/10.1182/blood.v110.11.5165.5165.

Full text

Abstract:

Abstract BACKGROUND. Patterns, prevalence, and associated pt variables of CML pts’ nonadherence (PNA) with ImRx are being better understood. Reducing ImRx PNA may impact on treatment outcomes. Various AESs have been proposed but their perceived value and clinical applicability to treating MDs are unknown. OBJECTIVES. 1. Describe the perceptions of ImRx prescribing MDs of the utility (in terms of FX, FB, CO) of 13 AESs. 2. Describe MD rankings of the applicability in daily practice of each AES. DESIGN AND SUBJECTS. MD data subset from prospective, 90d observational, open-label, multicenter stud

APA, Harvard, Vancouver, ISO, and other styles

43

Raphael, Kalani L., Tom Greene, Guo Wei та ін. "Sodium Bicarbonate Supplementation and Urinary TGF-β1 in Nonacidotic Diabetic Kidney Disease". Clinical Journal of the American Society of Nephrology 15, № 2 (2020): 200–208. http://dx.doi.org/10.2215/cjn.06600619.

Full text

Abstract:

Background and objectivesIn early-phase studies of individuals with hypertensive CKD and normal serum total CO2, sodium bicarbonate reduced urinary TGF-β1 levels and preserved kidney function. The effect of sodium bicarbonate on kidney fibrosis and injury markers in individuals with diabetic kidney disease and normal serum total CO2 is unknown.Design, setting, participants, & measurementsWe conducted a randomized, double-blinded, placebo-controlled study in 74 United States veterans with type 1 or 2 diabetes mellitus, eGFR of 15–89 ml/min per 1.73 m2, urinary albumin-to-creatinine ratio (U

APA, Harvard, Vancouver, ISO, and other styles

44

Schiffer, Charles A., Jorge E. Cortes, Giuseppe Saglio, et al. "The Association Of Dasatinib-Induced Lymphocytosis With Treatment Outcome In Patients With Chronic Myeloid Leukemia (CML)." Blood 122, no. 21 (2013): 2741. http://dx.doi.org/10.1182/blood.v122.21.2741.2741.

Full text

Abstract:

Abstract Background Clonal proliferation of T/NK cells has been noted after the treatment of CML patients with dasatinib. Previous reports have suggested that persistent expansion of clonal cytotoxic T cells or NK cells in dasatinib-treated patients may be associated with higher response rates and increased occurrence of pleural effusions. This retrospective study analyzed the incidence of lymphocytosis and its association with response, progression-free survival (PFS) and overall survival (OS), and pleural effusion in a large sample of dasatinib-treated patients. Methods Analyses were conduct

APA, Harvard, Vancouver, ISO, and other styles

45

Giné, Eva, Jordina Rovira, Alejandra Martinez-Trillos, et al. "Initial Features and Outcome Are Similar in Patients with Lymphoplasmacytic Lymphoma Regardless They Meet or Not Criteria of Waldenström Macroglobulinemia,." Blood 118, no. 21 (2011): 3677. http://dx.doi.org/10.1182/blood.v118.21.3677.3677.

Full text

Abstract:

Abstract Abstract 3677 Lymphoplasmacytic lymphoma (LPL) is a very heterogeneous disease from the clinical stand point, including the fact that Waldenström macroglobulinemia (WM) can be recognized in a significant proportion of LPL cases. Whether LPL with and without criteria for WM differ in the clinical features and outcome is not well known and is the aim of the present study. For this purpose, 50 patients (median age, 67 years (range, 19 to 91; 50% males) with a tissue biopsy diagnostic of LPL or a bone marrow infiltration by LPL were included in the present study. Main clinic-biological c

APA, Harvard, Vancouver, ISO, and other styles

46

Ronsley, Rebecca, Erin E. Crotty, Nicholas A. Vitanza, et al. "MDB-27. OUTCOMES FOR CHILDREN TREATED FOR MEDULLOBLASTOMA USING A RADIATION-SPARING APPROACH: A REPORT FROM THE CHILDREN’S BRAIN TUMOR NETWORK." Neuro-Oncology 26, Supplement_4 (2024): 0. http://dx.doi.org/10.1093/neuonc/noae064.476.

Full text

Abstract:

Abstract OBJECTIVE To describe real-world outcomes in children with medulloblastoma treated with radiation-sparing chemotherapy in the USA. METHODS Clinical and molecular data were obtained from the Children’s Brain Tumor Network (CBTN), a multi-institutional collaboration to collect and freely share biological samples and longitudinal clinical data from consented patients. Patients with medulloblastoma treated with radiation-sparing regimens were included. Clinical data included patient demographics, stage, extent of resection, treatment regimen, and survival. Three-year overall survival (OS3

APA, Harvard, Vancouver, ISO, and other styles

47

Wickerson, Lisa, Denise Helm, Chaya Gottesman, et al. "Telerehabilitation for Lung Transplant Candidates and Recipients During the COVID-19 Pandemic: Program Evaluation." JMIR mHealth and uHealth 9, no. 6 (2021): e28708. http://dx.doi.org/10.2196/28708.

Full text

Abstract:

Background The COVID-19 pandemic resulted in a rapid shift from center-based rehabilitation to telerehabilitation for chronic respiratory disease and lung transplantation due to infection control precautions. Clinical experience with this delivery model on a large scale has not been described. Objective The aim of this study is to describe usage and satisfaction of providers and lung transplant (LTx) candidates and recipients and functional outcomes following the broad implementation of telerehabilitation with remote patient monitoring during the first wave of the COVID-19 pandemic. Methods Th

APA, Harvard, Vancouver, ISO, and other styles

48

Mizuno, Shohei, Luuk Gras, Laurien Baaij, et al. "Impact of Age on Outcome in Newly Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous Hematopoietic Cell Transplantation from the Worldwide Network for Blood and Marrow Transplantation Global Study." Blood 142, Supplement 1 (2023): 785. http://dx.doi.org/10.1182/blood-2023-179153.

Full text

Abstract:

Background ： Induction therapy with proteasome inhibitors and immunomodulatory agents followed by autologous hematopoietic cell transplantation (HCT) is considered standard of care in front line multiple myeloma (MM) treatment. Utilization of autologous HCT is increasing worldwide in younger and older patients in light of improvements in supportive care and infrastructure. However, global perspectives on patterns of patient age and the impact of age on outcomes in this population are scarce. In the current analysis of global registry data, we focused on the age distribution and the association

APA, Harvard, Vancouver, ISO, and other styles

49

Wenzel, Mike, Florestan Koll, Benedikt Hoeh, et al. "Cancer-control outcomes of metastatic castration resistant prostate cancer patients with BRCA -gene or tumor suppressor mutations undergoing 177-lutetium PSMA radioligand therapy." Journal of Clinical Oncology 43, no. 5_suppl (2025): 71. https://doi.org/10.1200/jco.2025.43.5_suppl.71.

Full text

Abstract:

71 Background: Several tumor gene mutations are known for metastatic castration-resistant prostate cancer (mCRPC) are known. The individual response to 177-Lutetium Prostate-specific membrane antigen (Lu-PSMA) therapy is under current investigation regarding the genomic profile of mCRPC patients. Methods: We relied on the FRAMCAP database and compared progression-free (PFS) and overall survival (OS) rates of mCRPC patients with Breast Cancer related antigen ( BRCA ) or tumor suppressor gene mutations ( TP53, PTEN, RB1 [TSG]). Especially, subgroup analyses were performed for Lu-PSMA-treated mCR

APA, Harvard, Vancouver, ISO, and other styles

50

Siegel, David S., Paul G. Richardson, Meletios A. Dimopoulos, et al. "Efficacy and Safety Of Pomalidomide Plus Low-Dose Dexamethasone In Advanced Multiple Myeloma: Results Of Randomized Phase 2 and 3 Trials (MM-002/MM-003)." Blood 122, no. 21 (2013): 3185. http://dx.doi.org/10.1182/blood.v122.21.3185.3185.

Full text

Abstract:

Abstract Introduction Few treatments options are available for patients (pts) with relapsed/refractory multiple myeloma (RRMM) who have previously been treated with lenalidomide (LEN) and bortezomib (BORT), and their prognosis is poor. Pomalidomide (POM) is a distinct IMiD® immunomodulatory agent with a mechanism of action consisting of direct anti-myeloma, stromal-support inhibitory, and immunomodulatory effects. In randomized phase 2 and 3 trials (MM-002 and MM-003), POM plus low-dose dexamethasone (POM+LoDEX) demonstrated marked efficacy in RRMM pts who had received multiple prior therapies

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!